Kinnate Biopharma Inc.

Equities

KNTE

US49705R1059

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:30:00 03/04/2024 am IST			5-day change	1st Jan Change
2.65 ^USD	-0.38%		-.--%	+11.81%

03/04	Kinnate Biopharma Inc. Announces Board Resignations	CI
03/04	Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	CI

Kinnate Biopharma Inc. Announces Stepdown of Eric Murphy as Chief Scientific Officer, Effective December 3, 2021

October 29, 2021 at 01:35 am IST

Kinnate Biopharma Inc. announced that the company?s Chief Scientific Officer, Eric Murphy, Ph.D., will step down from that role on December 3, 2021 to pursue a new opportunity. Dr. Murphy will remain an important scientific adviser to Kinnate and will continue to support the company by serving on its Scientific Advisory Board.

Latest news about Kinnate Biopharma Inc.

Kinnate Biopharma Inc. Announces Board Resignations	03/04	CI
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	03/04	CI
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	03/04	CI
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from S&P TMI Index	03/04	CI
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
Kinnate Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
North American Morning Briefing : Markets Steady -2-	26/03	DJ
Kinnate Biopharma Sells Cancer Treatment Assets to Pierre Fabre Laboratories	01/03	MT
Stifel Raises Kinnate Biopharma's Price Target to $2.59 From $1.50, Keeps Hold Rating	26/02	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	17/02	MT
Wedbush Adjusts Kinnate Biopharma's PT to $2.34 From $2 on Heels of Announced Sale Agreement With XOMA, Keeps Neutral Rating	16/02	MT
XOMA Agrees to Acquire Kinnate Biopharma	16/02	MT
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million.	16/02	CI
Kinnate Biopharma Plans to Further Reduce Workforce by 56%	17/01	MT
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Biotechnology Index	15/12	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	16/11	MT
Top Midday Gainers	16/11	MT
Top Premarket Gainers	15/11	MT
Kinnate Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
North American Morning Briefing : Fed Seen Holding -2-	20/23/20	DJ
Jefferies Cuts Price Target on Kinnate Biopharma to $2 From $31, Maintains Buy Rating	19/23/19	MT
Sector Update: Health Care Stocks Mixed Premarket Tuesday	19/23/19	MT
Sector Update: Health Care	19/23/19	MT
HC Wainwright Downgrades Kinnate Biopharma to Neutral From Buy	19/23/19	MT
Wedbush Downgrades Kinnate Biopharma to Neutral From Outperform After News of Restructuring, Workforce Reduction; Cuts PT to $2 From $14	19/23/19	MT

Chart Kinnate Biopharma Inc.

Duration

Period

More charts

Company Profile

Kinnate Biopharma Inc. is a clinical-stage precision oncology company. The Company is focused on the discovery, design, and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. The Companyâs product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor which was designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC), a cancer of the bile ducts in the liver, and urothelial carcinoma (UC), a cancer of the bladder lining, as well as other solid tumors. Its early-stage programs include a c-MET inhibitor that targets resistant variants and a brain penetrant CDK4 selective program. The Company concentrates its efforts on addressing known oncogenic drivers for targeted therapies and to overcome the limitations associated with existing cancer therapies, such as non-responsiveness or the development of acquired and intrinsic resistance.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KINNATE BIOPHARMA INC.	+11.81%	125M
MODERNA, INC.	+54.05%	58.71B
IQVIA HOLDINGS INC.	-2.02%	41.31B
LONZA GROUP AG	+38.51%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B
BIO-TECHNE CORPORATION	+2.89%	12.51B
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B
MEDPACE HOLDINGS, INC.	+27.49%	12.08B

Other Biotechnology & Medical Research